Combinations Key For Amgen’s Lumakras, But PD-1/L1 Data Held Until August

Combo Importance Increases With Sales Growth Slowing

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

A World Conference on Lung Cancer abstract shows responses to Lumakras with a SHP2 inhibitor but closely watched results for anti-PD-1/L1 combinations are under embargo until the meeting next month.

Lungs icon, anatomy, health care concept
Amgen's first Lumakras combination therapy results in lung cancer will be presented at WCLC • Source: Shutterstock

One of two highly anticipated datasets for Amgen, Inc.’s KRAS G12C inhibitor Lumakras (sotorasib) in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC) was released late on 12 July when the World Conference on Lung Cancer (WCLC) published abstracts for next month’s meeting. The initial efficacy findings for use with Revolution Medicines, Inc.’s SHP2 inhibitor are inconclusive due to small NSCLC patient numbers, but the safety results appear reasonable ahead of anti-PD-1/L1 combination results being unveiled at the conference in August.

Amgen was the first company to bring a KRAS G12C inhibitor to the market and has maintained its lead even...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D